N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.168 NOK 1.59% Market Closed
Market Cap: 708m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Wall Street
Price Targets

NYKD Price Targets Summary
Nykode Therapeutics ASA

Wall Street analysts forecast NYKD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYKD is 23.052 NOK with a low forecast of 10.1 NOK and a high forecast of 52.5 NOK.

Lowest
Price Target
10.1 NOK
366% Upside
Average
Price Target
23.052 NOK
963% Upside
Highest
Price Target
52.5 NOK
2 322% Upside
Nykode Therapeutics ASA Competitors:
Price Targets
RARE
Ultragenyx Pharmaceutical Inc
92% Upside
1952
Everest Medicines Ltd
15% Downside
STRO
Sutro Biopharma Inc
209% Upside
206650
EuBiologics Co Ltd
5% Downside
TSVT
2Seventy Bio Inc
104% Upside
MDGL
Madrigal Pharmaceuticals Inc
17% Upside
688266
Suzhou Zelgen Biopharmaceuticals Co Ltd
14% Downside
ALGEN
Genoway SA
93% Upside

Revenue
Forecast

Revenue Estimate
Nykode Therapeutics ASA

For the last 6 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 154%. The projected CAGR for the next 3 years is -63%.

154%
Past Growth
-63%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Nykode Therapeutics ASA

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Nykode Therapeutics ASA

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NYKD's stock price target?
Price Target
23.052 NOK

According to Wall Street analysts, the average 1-year price target for NYKD is 23.052 NOK with a low forecast of 10.1 NOK and a high forecast of 52.5 NOK.

What is Nykode Therapeutics ASA's Revenue forecast?
Projected CAGR
-63%

For the last 6 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 154%. The projected CAGR for the next 3 years is -63%.

Back to Top